Artivion, Inc.

NYSE:AORT Stock Report

Market Cap: US$2.2b

Artivion Management

Management criteria checks 3/4

Artivion's CEO is Pat Mackin, appointed in Sep 2014, has a tenure of 11.17 years. total yearly compensation is $5.51M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 1.69% of the company’s shares, worth $37.51M. The average tenure of the management team and the board of directors is 4.7 years and 9.1 years respectively.

Key information

Pat Mackin

Chief executive officer

US$5.5m

Total compensation

CEO salary percentage14.64%
CEO tenure11.2yrs
CEO ownership1.7%
Management average tenure4.7yrs
Board average tenure9.1yrs

Recent management updates

Recent updates

Artivion (NYSE:AORT) Might Have The Makings Of A Multi-Bagger

Sep 11
Artivion (NYSE:AORT) Might Have The Makings Of A Multi-Bagger

Share Growth And Strong Clinical Results Continue To Support The Artivion Story

Sep 03

Revenues Tell The Story For Artivion, Inc. (NYSE:AORT) As Its Stock Soars 37%

Aug 12
Revenues Tell The Story For Artivion, Inc. (NYSE:AORT) As Its Stock Soars 37%

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jul 10
Is Artivion (NYSE:AORT) Using Too Much Debt?
User avatar

Global Heart Valve Demand Will Expand Future Markets

Advances in medical technology, strong clinical evidence, and new product launches are expanding Artivion's market opportunities and enabling premium pricing for top-line growth.

Artivion, Inc.'s (NYSE:AORT) 29% Jump Shows Its Popularity With Investors

May 09
Artivion, Inc.'s (NYSE:AORT) 29% Jump Shows Its Popularity With Investors

Artivion, Inc.'s (NYSE:AORT) CEO Looks Like They Deserve Their Pay Packet

May 06
Artivion, Inc.'s (NYSE:AORT) CEO Looks Like They Deserve Their Pay Packet

Here's Why Artivion (NYSE:AORT) Has A Meaningful Debt Burden

Apr 08
Here's Why Artivion (NYSE:AORT) Has A Meaningful Debt Burden

Artivion, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Feb 27
Artivion, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?

Feb 13
Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?

Why Investors Shouldn't Be Surprised By Artivion, Inc.'s (NYSE:AORT) P/S

Jan 09
Why Investors Shouldn't Be Surprised By Artivion, Inc.'s (NYSE:AORT) P/S

Artivion: Current Valuation Seems Stretched.

Dec 26

Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

Dec 19
Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

When Should You Buy Artivion, Inc. (NYSE:AORT)?

Nov 07
When Should You Buy Artivion, Inc. (NYSE:AORT)?

Returns At Artivion (NYSE:AORT) Are On The Way Up

Sep 28
Returns At Artivion (NYSE:AORT) Are On The Way Up

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Sep 06
Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Is Artivion (NYSE:AORT) A Risky Investment?

Jun 28
Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Jun 21

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 08
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jan 13
Is Artivion (NYSE:AORT) Using Too Much Debt?

Artivion Stock: A First Assessment

Dec 27

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23
Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

CEO Compensation Analysis

How has Pat Mackin's remuneration changed compared to Artivion's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$9m

Jun 30 2025n/an/a

-US$18m

Mar 31 2025n/an/a

-US$21m

Dec 31 2024US$6mUS$807k

-US$13m

Sep 30 2024n/an/a

-US$842k

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$3mUS$776k

-US$31m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$7mUS$750k

-US$19m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$5mUS$728k

-US$15m

Sep 30 2021n/an/a

US$2m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$3mUS$606k

-US$17m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$6mUS$689k

US$2m

Sep 30 2019n/an/a

US$2m

Jun 30 2019n/an/a

US$3m

Mar 31 2019n/an/a

US$709k

Dec 31 2018US$3mUS$660k

-US$3m

Compensation vs Market: Pat's total compensation ($USD5.51M) is about average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Pat's compensation has increased whilst the company is unprofitable.

CEO

Pat Mackin (58 yo)

11.2yrs
Tenure
US$5,511,940
Compensation

Mr. James Patrick Mackin, also known as Pat, has been a Director of Route 92 Medical, Inc. since November 2025. He has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as Cr...

Leadership Team

NamePositionTenureCompensationOwnership
James Mackin
Chairman11.2yrsUS$5.51m1.69%
$ 37.5m
Lance Berry
EVP, COO1.9yrsUS$2.57m0.26%
$ 5.7m
Jean Holloway
Senior VP10.6yrsUS$1.52m0.34%
$ 7.7m
John Davis
Senior VP & Chief Commercial Officer1.8yrsUS$1.49m0.42%
$ 9.3m
Marshall Stanton
Senior VP of Clinical Research & Chief Medical Officer4.7yrsUS$1.29m0.094%
$ 2.1m
Amy Horton
VP & Chief Accounting Officer19.3yrsUS$1.06m0.29%
$ 6.3m
Matthew Getz
VP of Human Resources & Chief Human Resources Officer6.3yrsno data0.072%
$ 1.6m
Jason Asper
Senior VP and Chief Strategy & Digital Officerless than a yearno datano data
Robert Thomson
Vice President of Research & Development2.4yrsno datano data
4.7yrs
Average Tenure
56yo
Average Age

Experienced Management: AORT's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Mackin
Chairman11.1yrsUS$5.51m1.69%
$ 37.5m
James Bullock
Independent Director9.1yrsUS$217.49k0.14%
$ 3.2m
Thomas Ackerman
Independent Director21.9yrsUS$229.99k0.32%
$ 7.0m
Anthony Semedo
Independent Director4.1yrsUS$217.49k0.083%
$ 1.8m
Daniel Bevevino
Independent Director21.9yrsUS$234.99k0.32%
$ 7.0m
Jeffrey Burbank
Independent Presiding Director8.2yrsUS$264.99k0.11%
$ 2.5m
Jon Salveson
Independent Director13.5yrsUS$214.99k0.27%
$ 6.1m
Marna Borgstrom
Independent Director7.4yrsUS$219.99k0.10%
$ 2.3m
Elizabeth Hoff
Independent Director3.1yrsUS$214.16k0.057%
$ 1.3m
9.1yrs
Average Tenure
65yo
Average Age

Experienced Board: AORT's board of directors are considered experienced (9.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/26 22:51
End of Day Share Price 2025/11/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Artivion, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
William PlovanicCanaccord Genuity
David TurkalyCitizens JMP Securities, LLC